Stoke Therapeutics
STOK
92 hedge funds and large institutions have $569M invested in Stoke Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 14 closing their positions.
17,033% more call options, than puts
Call options by funds: $514K | Put options by funds: $3K
110% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 20
0.78% less ownership
Funds ownership: 110.69% → 109.91% (-0.78%)
7% less funds holding
Funds holding: 99 → 92 (-7)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
35% less capital invested
Capital invested by funds: $871M → $569M (-$301M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$15.4M |
| 2 |
Millennium Management
New York
|
+$7.93M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.85M |
| 4 |
BlackRock
New York
|
+$4.25M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.69M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$7.69M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$6.46M |
| 4 |
SG Americas Securities
New York
|
-$3.84M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.77M |
STOK Hedge Fund Activity: Q2 2022 in Review
92 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2022, worth a combined $569M — down 35% from $871M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of STOK and 10 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 42 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $15.4M. The largest seller was State Street, cutting an estimated $8.69M.
- 92 institutional investors held Stoke Therapeutics (STOK) as of Q2 2022, down from 99 in Q1 2022.
- Funds reported $569M of Stoke Therapeutics stock for Q2 2022, down 35% quarter-over-quarter.
- 10 funds opened new Stoke Therapeutics positions in Q2 2022 and 14 closed out, a net change of -4 holders.
- The largest Stoke Therapeutics buyer in Q2 2022 was Bank of Montreal, an estimated $15.4M added.
- The largest Stoke Therapeutics seller in Q2 2022 was State Street, an estimated $8.69M sold.
Based on aggregated 13F filings for Q2 2022.